Access Bio signs ₩5.0bn supply contract with P&G for home tests

Access Bio · KOSDAQ · 950130 · Oct 20, 2026 · Supply contracts

Access Bio filed a supply contract with The Procter & Gamble Manufacturing Company for the Flu A + Flu B + COVID-19 Combo Home Test, with a contract amount of ₩5.0bn. The filing reports this as 15.9% of revenue, and the contract period runs from Oct 15, 2026 to Oct 14, 2027.

Key facts

Contract nameFlu A + Flu B + COVID-19 Combo Home Test supply contract
CounterpartyThe Procter & Gamble Manufacturing Company
Contract amount₩5.0bn
% of revenue (as reported)15.9%
Period startOct 15, 2026
Period endOct 14, 2027

Comparison

Amount as % of FY2025 revenue (calculated)22597.4%
Revenue 2025₩22m
Revenue 2024₩82m
Revenue 2023₩267m

Context

By our calculation, the contract amount is 22597.4% of FY2025 revenue.

Key metrics

Supply contracts

Supply contracts, last 12 months₩5.0bn As of Oct 20, 2026 Source 1
Supply contracts vs prior-year revenue22597.4% As of Oct 20, 2026 Source 1
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Source: DART (Financial Supervisory Service) · Original filing on DART ↗ (opens the Financial Supervisory Service's DART site)